Related Experiment Video
Updated: Aug 28, 2025

15:07
VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma
Published on: December 28, 2015
26.8K
Do we have to exclude all relapsed diffuse large B-cell lymphoma patients not in complete remission from autologous
Christian Gisselbrecht1, David Sibon2
1Hopital Saint Louis, Paris Cité University, Paris, France.
British Journal of Haematology
|September 19, 2022
Abstract:
Treatment of relapsed/refractory diffuse large B-cell lymphoma remains a challenge with the advent of chimaeric antigen receptor CAR-T cell treatment. Whether or not eligibility criteria should replace the standard autologous transplantation is debated. By using PET-derived parameters, the report of Cherng and colleagues suggests that patients with positive residual mass can have a five-year survival of 54% with standard treatment.

